28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.
The JP Morgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Affymax Inc and Infinity Pharmaceuticals Inc. Investigational drugs from Affymax, including Hematide (in collaboration with Takeda Pharmaceutical Co Ltd), and from Infinity Pharmaceuticals, including IPI-926, retaspimycin hydrochloride, IPI-493 and IPI-940, are discussed.
Croasdell
Gary
G
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. gary.croasdell@thomsonreuters.com
Mason
Vicki L
VL
D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000700:Analgesics / Q000627:therapeutic use; D000740:Anemia / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry / Q000191:economics; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D053823:Hedgehog Proteins / Q000378:metabolism; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D010455:Peptides / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000700:Analgesics; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D053823:Hedgehog Proteins; D006397:Hematinics; D010455:Peptides; D011092:Polyethylene Glycols; D000099252:Fatty Acid Amide Hydrolases; C514771:hematide